Arcturus Therapeutics Q1 2026 Earnings Preview
2026-05-06 17:35:56 ET
More on Arcturus Therapeutics
- Arcturus Therapeutics: Downgrading To 'Hold' As CF Program Shifts Population Focus
- Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
- Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
- Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026
- Seeking Alpha’s Quant Rating on Arcturus Therapeutics
Read the full article on Seeking Alpha
For further details see:
Arcturus Therapeutics Q1 2026 Earnings PreviewNASDAQ: ARCT
ARCT Trading
-9.05% G/L:
$7.44 Last:
175,867 Volume:
$7.96 Open:



